Clinical Pharmacokinetics of Sertraline (original) (raw)
Boyer WF, Feighner JP. The efficacy of selective serotonin reuptake inhibitors in depression. In: Feighner JP, Boyer WF, editors. Selective serotonin re-uptake inhibitors, perspectives in psychiatry I. New York: John Wiley & Sons, 1991: 89–108 Google Scholar
Doogan DP, Caillard V. Sertraline: a new antidepressant. J Clin Psychiatry 1988; 49 Suppl. 8: 46–51 PubMed Google Scholar
Henry JA. Overdose and safety with fluvoxamine. Int Clin Psychopharmacol 1991; 6 Suppl. 3: 41–7 PubMed Google Scholar
Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992; 11(11): 930–57 PubMedCAS Google Scholar
Owens MJ, Morgan WN, Plott ST, et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther 1997; 283: 1305–22 PubMedCAS Google Scholar
Tremaine LM, Welch WM, Ronfeld RA. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 1989; 17: 542–50 PubMedCAS Google Scholar
Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1992; 6 Suppl. 2: 11–21 Google Scholar
Zoloft® product information. New York: Roerig, Division of Pfizer Inc, 2001
Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants [letter]. Am J Psychiatry 1988; 145: 1478 PubMedCAS Google Scholar
Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239–48 PubMedCAS Google Scholar
van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993; 24: 203–20 PubMed Google Scholar
Brosen K. Recent developments in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220–39 PubMedCAS Google Scholar
De Vane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992; 53 Suppl. 2: 13–20 Google Scholar
Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28 PubMedCAS Google Scholar
Preskorn SH, editor. Interaction profile of sertraline with commonly prescribed medications. J Clin Psychiatry 1996; 57 Suppl. 1:3–28 Google Scholar
Fouda HG, Ronfeld RA. Gas chromatographic-mass spectrometric analysis and preliminary human pharmacokinetics of sertraline, a new antidepressant drug. J Chromatogr Biomed Appl 1987; 417: 197–202 CAS Google Scholar
Saletu B, Grunberger J, Linzmayer L. On central effects of serotonin re-uptake inhibitors: quantitative EEG and psycho metric studies with sertraline and zimelidine. J Neural Transm 1986; 67: 241–66 PubMedCAS Google Scholar
Wiener HL, Kramer HK, Reith MEA. Separation and determination of sertraline and its metabolite, desmethylsertraline, in mouse cerebral cortex by reversed-phase high-performance liquid chromatography. J Chromatogr 1990; 527: 467–72 PubMedCAS Google Scholar
Gupta RN, Dziurdzy SA. Therapeutic monitoring of sertraline. Clin Chem 1994; 40: 498–9 PubMedCAS Google Scholar
Rogowsky D, Marr M, Long G, et al. Determination of sertraline and desmethylsertraline in human serum using copolymeric bonded-phase extraction, liquid chromatography and gas chromatography-mass spectrometry. J Chromatogr 1994; 655: 138–41 CAS Google Scholar
Fuller RW, Hemrick-Luecke SK, Litterfield ES, et al. Comparison of desmethylsertraline with sertraline as a monoamine uptake inhibitor in vivo. Life Sci 1995; 19: 135–49 CAS Google Scholar
Vatassery GT, Holden LA, Hazel DK, et al. Analysis of sertraline and desmethylsertraline in human plasma and red blood cells. Clin Biochem 1997; 30: 565–8 PubMedCAS Google Scholar
Lucca L, Gentilini G, Lopez-Silva S, et al. Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by; high-performance liquid chromatography. Ther Drug Monit 2000; 22: 271–6 PubMedCAS Google Scholar
Patel J, Spencer EP, Flanagan RJ. HPLC of sertraline and norsertraline in plasma or serum. Biomed Chromatogr 1996; 10: 351–4 PubMedCAS Google Scholar
Demolis JL, Angebaud P, Grange JD, et al. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996; 42: 394–7 PubMedCAS Google Scholar
Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 1998; 37: 386–94 PubMedCAS Google Scholar
Ronfeld RA, Wilner KD, Baris BA. Sertraline: chronopharmacokinetics and the effect of coadministration with food. Clin Pharmacokinet 1997; 32 Suppl. 1: 50–5 PubMedCAS Google Scholar
Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-desmethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32 Suppl. 1:22–30 PubMedCAS Google Scholar
De Vane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994; 97 Suppl. 6A: 13–23 Google Scholar
Levine B, Jenkins AJ, Smialek JE. Distribution of sertraline in postmortem cases. J Anal Toxicol 1994; 18: 272–4 PubMedCAS Google Scholar
Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes mediating sertraline biotransformation: seeking attribution. J Clin Psychopharmacol 1999; 19: 489–93 PubMedCAS Google Scholar
Xu Z-H, Wang W, Zhao X-J, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol 1999; 48: 416–23 PubMedCAS Google Scholar
Kobayashi K, Ishizuka T, Shimada N, et al. Sertraline Ndemethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 1999; 27: 763–6 PubMedCAS Google Scholar
Hamelin BA, Trugeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60: 512–21 PubMedCAS Google Scholar
Wang JH, Lio ZQ, Wang W, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharm Ther 2001; 70: 42–7 CAS Google Scholar
Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 1993; 52: 1023–9 PubMedCAS Google Scholar
Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacol 1994; 114: 559–65 CAS Google Scholar
Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effect of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996; 14: 225–31 PubMedCAS Google Scholar
Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit 2000; 22: 446–54 PubMedCAS Google Scholar
March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder. JAMA 1998; 280: 1752–6 PubMedCAS Google Scholar
Axelson O, Castleman B, Epstein S, et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 2002; 41(9): 1037–44 PubMed Google Scholar
Kristensen JH, Ilett KF, Dusci LJ, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998; 45: 453–7 PubMedCAS Google Scholar
Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry 1997; 154: 1255–60 PubMedCAS Google Scholar
Dodd S, Stocky A, Buist A, et al. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000; 15: 261–4 CAS Google Scholar
Wisner KL, Perel JM, Blumer J. Serum sertraline and N-desmethylsertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998; 155: 690–2 PubMedCAS Google Scholar
Mammen OK, Perel JM, Rudolph G, et al. Sertraline and norsertraline levels in three breastfed infants. J Clin Psychiatry 1997; 58: 100–3 PubMedCAS Google Scholar
Epperson CN, Anderson GM, McDougle CJ. Sertraline and breastfeeding. N Engl J Med 1997; 336: 1189–90 PubMedCAS Google Scholar
Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609–10 PubMedCAS Google Scholar
Schwenk MH, Verga MA, Wagner JD. Hemodialyzability of sertraline. Clin Nephrology 1995; 44: 121–4 CAS Google Scholar
Barros J, Asnis G. An interaction of sertraline and desipramine [letter]. Am J Psychiatry 1993; 150: 1751 PubMedCAS Google Scholar
Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants. Am J Psychiatry 1993; 150: 1125–6 PubMedCAS Google Scholar
Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine co-administered with sertraline or fluoxetine. J Clin Psychopharmacol 1994; 14: 90–8 PubMedCAS Google Scholar
Zussman BD, Davie CC, Fowles SE, et al. Sertraline, like other SSRIs, is a significant inhibitor of desipramine metabolism in vivo. Br J Clin Pharmacol 1995; 39: 550–1 Google Scholar
Erickson SM, Carson C, Grimsley SR, et al. Effect of sertraline on steady-state concentration of imipramine and its metabolites [abstract]. Pharmacotherapy 1994; 14: 368 Google Scholar
Apseloff G, Wilner KD, Gerber N, et al. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997; 32 Suppl. 1:37–42 PubMedCAS Google Scholar
Gardner MJ, Baris BA, Wilner KD, et al. Effect of sertraline on the pharmacokinetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997; 32 Suppl. 1: 43–9 PubMedCAS Google Scholar
Joblin M, Ghose K. Possible interaction of sertraline with carbamazepine [letter]. N Z Med J 1994; 107: 43 PubMedCAS Google Scholar
Apseloff G, Wilner KD, von Deutsch DA, et al. Sertraline does not alter steady-state concentrations or renal clearance of lithium in healthy volunteers. J Clin Pharmacol 1992; 32: 643–6 PubMedCAS Google Scholar
Hassan PC, Sproule BA, Naranjo CA, et al. Dose-response evaluation of the interaction between sertraline and alprazolam in vivo. J Clin Psychopharmacol 2000; 20: 150–8 PubMedCAS Google Scholar
Tremarne LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997; 32 Suppl. 1:31–6 Google Scholar
Rapeport WG, Williams SA, Muirhead DC, et al. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996; 57 Suppl. 1:20–3 PubMedCAS Google Scholar
Khan A, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 2000; 61: 526–7 PubMedCAS Google Scholar
Ronfeld RA, Shaw GL, Tremaine LM. Distribution and pharmacokinetics of the selective 5-HT uptake blockers sertraline in man, rat and dog [abstract]. Psychopharmacology 1988; 96 Suppl. 1: 269 Google Scholar
Crewe HK, Lennard MS, Tucher GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992; 34: 262–5 PubMedCAS Google Scholar
Sproule BA, Otton SV, Cheung SW, et al. CYP2D6 inhibition in patients treated with sertraline. J Clin Psychopharmacol 1997; 17: 102–6 PubMedCAS Google Scholar
Alfaro CL, Lam YWF, Simpson J, et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, paroxetine, or sertraline. J Clin Psychopharmacol 1999; 19: 155–63 PubMedCAS Google Scholar
Alfaro CL, Lam YWF, Simpson J, et al. CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a cross over study: intraindividual variability and plasma concentration correlation. J Clin Pharmacol 2000; 40: 58–66 PubMedCAS Google Scholar
Liston HL, DeVane CL, Boulton DW, et al. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002; 22: 169–73 PubMedCAS Google Scholar
Jurima-Romet M, Wright M, Neigh S. Terfenadine-antidepressant interactions: an in vitro inhibition study using human liver microsomes. Br J Clin Pharmacol 1998; 45: 318–21 PubMedCAS Google Scholar
von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23–31 CAS Google Scholar
Preskorn SH, Alderman J, Greenblatt DJ, et al. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo. Psychopharmacol Bull 1997; 33: 659–65 PubMedCAS Google Scholar
Hesse LM, Venkakakrishnan K, Court MH, et al. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 2000; 28: 1176–83 PubMedCAS Google Scholar
Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. J Clin Psychopharmacol 2000; 20: 585–6 PubMedCAS Google Scholar
DeVane CL, Donovan JL, Liston HL, et al. Lack of venlafaxine CYP3A4 inhibitory effects on oral and IV model substrates [abstract]. European College of Neuropsychopharmacology (ECNP); 2002 Oct 6; Barcelona. Eur Neuropsychopharmacol 2002; 12 (Suppl. 3): 229 Google Scholar
Smith RB, et al. Clonazepam and sertraline: absence of drug interaction in a multiple-dose study. J Clin Psychopharmacol 2000; 20: 19–27 PubMed Google Scholar
Rapeport WG, Coates PE, Dewland PM, et al. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J Clin Psychiatry 1996; 57 Suppl. 1: 16–9 PubMedCAS Google Scholar
Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997; 17: 284–91 PubMedCAS Google Scholar
Kurtz DL, Bergstrom RF, Goldberg MJ, et al. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997; 62: 145–56 PubMedCAS Google Scholar
DeVane CL. Clinical implications of dose-dependent cytochrome P-450 drug-drug interactions with antidepressants. Hum Psychopharmacol Clin Exp 1998; 13: 329–36 CAS Google Scholar
Solai LK, Mulsant BH, Pollock BG, et al. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997; 58: 440–3 PubMedCAS Google Scholar
Takhar J, Williamson P. Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin-dependent diabetes mellitus patient. Can J Clin Pharmacol 1999; 6: 12–4 PubMedCAS Google Scholar
Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: role of CYP 3A4 and CYP 2C8 in 10, 11-epoxide formation. Biochem Pharmacol 1994; 47: 1969–79 PubMedCAS Google Scholar
Markowitz JS, De Vane CL. Rifampin induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. J Clin Psychopharmacol 2000; 20: 109–10 PubMedCAS Google Scholar
Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7: 163–6 PubMedCAS Google Scholar
Lamictal® (lamotrigine) product information. Research Triangle Park (NC): GlaxoWellcome Inc, 1999
Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997; 17: 107–9 PubMedCAS Google Scholar
Nelson MH, Birnbaum AK, Remmel RP. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res 1001; 44: 71-82
Pinninti NR, de Leon J. Interaction of sertraline with clozapine. J Clin Psychopharmacol 1997; 17: 119–20 PubMedCAS Google Scholar
Spina E, Avenoso A, Salemi M, et al. Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 2000; 33: 213–7 PubMedCAS Google Scholar
Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001; 23: 410–3 PubMedCAS Google Scholar
Lee MS, Han CS, You YW, et al. Co-administration of sertraline and haloperidol. Psychiatry Clin Neurosci 1998; 52: S193–8 PubMedCAS Google Scholar
Williams SA, Wesnes K, Oliver SD, et al. Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol. J Clin Psychiatry 1996; 57 Suppl. 1: 7–11 PubMedCAS Google Scholar
Daniel WA, Syrek M, Haduch A, et al. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: in vivo and in vitro. Exp Toxicol Pathol 1999; 51: 309–14 PubMedCAS Google Scholar
Daniel WA, Syrek M, Haduch A, et al. The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat. J Pharm Pharmacol 2001; 53: 449–61 PubMedCAS Google Scholar
Hamilton SP, Nunes EV, Janal M, et al. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000; 9: 63–9 PubMedCAS Google Scholar
Allard S, Sainati SM, Roth-Schechter BF. Coadministration of short-term zolpidem with sertraline in healthy women. J Clin Pharmacol 1999; 39: 184–91 PubMedCAS Google Scholar
Lee AJ, Chan WK, Harralson AF, et al. The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin Ther 1999; 21: 1890–9 PubMedCAS Google Scholar
Lee DO, Lee CD. Serotonin syndrome in a child associated with erythromycin and sertraline. Pharmacotherapy 1999; 7: 894–6 Google Scholar
Sternbach HS. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13 PubMedCAS Google Scholar
Brannan SK, Talley BJ, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome [letter]. J Clin Psychopharmacol 1995; 15: 144 Google Scholar
Bhatara VS, Bandettini FC. Possible interaction between sertraline and tranylcypromine. Clin Pharm 1993; 12: 222–5 PubMedCAS Google Scholar
Ziegler MG, Wilner KD. Sertraline does not alter the beta-adrenergic blocking activity of atenolol in healthy male volunteers. J Clin Psychiatry 1996; 57 Suppl. 1: 12–5 PubMedCAS Google Scholar
Belpaire FM, Wijnant P, Temmerman A, et al. The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 1998; 54: 261–4 PubMedCAS Google Scholar
Bengtsson F, Lundmark J, Nordin C, et al. TDM of selective serotonin reuptake inhibitors treatment depression in the elderly reduces drug doses and costs [abstract]. Ther Drug Monit 1997; 19: 579 Google Scholar
Lundmark J, Bengtsson F, Nordin C, et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354–9 PubMedCAS Google Scholar